Dr Reddy's Laboratories (UK) Ltd: UK Public Sector Contracts Won & Awards

Companies House: Private Limited CompanyCambridgeNationwide (UK)Main market: Pharmaceutical products

Official UK PPONPGGG-3877-XTJGCompanies House01729064 ↗ · Active

Where they win
i

105 awards (101 for a named lot, 96%, 4 for a whole procedure with no lot named) · top CPV classes, shares of all 105 awards. An award may cover more than one class.

3360 Pharmaceutical products105 awards · 100% · 101 awards naming a lot + 4 whole-procedure awards
Attributable award value
i
£2.3mOn 7 of 105 award records; the five largest make 89%. Largest rows below.
Typical attributable award
i
£257k middle valuerobust · n=7

Where their buyers are
i

ITL1 region of the buyer office · known for 83 of 83 awarded procedures · each procedure counts once

Greater London41 procedures · 49%
Scotland23 procedures · 28%
Wales (Cymru)8 procedures · 10%
North West England7 procedures · 8%
South East England3 procedures · 4%
Yorkshire and the Humber1 procedure · 1%

Bidding record
i

Procurement Act 2023 award notices name every bidder · 10 notices name this supplier, covering 12 lots since 20 Aug 2025 · observed bids, not an estimate

Contract lots contested
i
0 won · 0 lostFewer than three decided lots: no rate is claimed.
Framework / DPS places
i
10 of 12Lots on 10 notices: a place is won per lot.
Authorities bid for
i
1

Bidder names come from Procurement Act 2023 award notices, which list every bidder (from 2025). Older notices name no bidders, so earlier contests do not appear here. Latest ten notices shown.

Who they sell to
i

Authorities named on this supplier’s published awards · ranked by distinct procedures · a framework or DPS adds one award record per appointed supplier

Authority type · official UK type when published, else name/id class, else not classified · by award records (a single panel can dominate)
i
  • NHS & health97%(102 awards)
    102 of 105 awards are NHS & health (97%).
  • Type not classified3%(3 awards)
    3 of 105 awards are Type not classified (3%).
AuthorityProceduresShareAward recordsLast activity
NHS Englandframework/DPS on 334149.4%5827 Aug 2026
The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")framework/DPS on 232327.7%3427 Jul 2026
The NHS Commissioning Board (operating under the name of NHS England)framework/DPS on 778.4%1830 Dec 2021
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)78.4%729 Jan 2026
ATAMIS LTD33.6%37 Jul 2023
eTenderwales11.2%117 Jun 2025
NHS England and NHS Improvement11.2%119 Jul 2022

Share = of the 83 procedures with an award naming this supplier. Last activity = award date, or notice publication when no award date was published.

Contracts ending
i

99 of 122 awards carry an end date, 31 estimated from the duration · not a retender forecast

ContractEndsPublished value
Range Generic & Biosimilar Cancer Medicines (unranked)3 Jan 2027 estimated£1,714,852 ceiling
Range of Generic Cancer Medicines (single supplier)3 Jan 2027 estimated£3,432,063 ceiling
Generic Drugs - Tablets & Capsules31 Jan 2027£170,199
Wave 15a - Hospital Only Products (DNW & DLN regions)31 Jan 2027£1 ceiling
Hospital Only Products31 Jan 2027£1 ceiling
Wave 15b - Orals (plus non-parenteral) products31 Jan 2027£1 ceiling
NHS National Framework for Transition products (Nilotinib and Ticagrelor)31 Jan 2027£22,097,000 ceiling
NHS National Framework for Transition products (Axitinib and Eltrombopag)31 Jan 2027£52,385,000 ceiling
Cancer Medicines (Group 2)31 Jan 2027£18,207,081 ceiling
Cancer Medicines31 Jan 2027£2,514,000 ceiling

Soonest 10 of 29.

Recent awards

Latest 30 of 105 award records naming this supplier

Contracts Finder adds 17 more procedures won by this supplier, mostly below the Find a Tender threshold or from before 2025. Each is counted once beside any Find a Tender copy; they are in the totals, not in this list.

Award / procedureAuthorityAwardedPublished value
NHS National Framework for Transition products (Nilotinib and Ticagrelor)NHS England12 Jun 2025£22,097,000
framework ceiling · 1 of 8 appointed suppliers
NHS National Framework for Transition products (Nilotinib and Ticagrelor)NHS England12 Jun 2025£22,097,000
framework ceiling · 1 of 8 appointed suppliers
Cancer MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£2,514,000 †
framework ceiling · 1 of 6 appointed suppliers
NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026NHS EnglandNot published£813,863,584 †
framework ceiling · 1 of 25 appointed suppliers
Generic HIV MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£3,636,988 †
framework ceiling · 1 of 10 appointed suppliers
NHS National Framework for Transition Products (Nintedanib and Dalbavancin)NHS EnglandNot published£14,758,000 †
framework ceiling · 1 of 6 appointed suppliers
Gastrointestinal, Endocrine, Blood, and Multiple Sclerosis MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£3,594,493 †
framework ceiling · 1 of 20 appointed suppliers
Denosumab (Osteoporosis) and Ferric CarboxymaltoseThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£2,254,091 †
framework ceiling · 1 of 11 appointed suppliers
NintedanibThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£1,400,387 †
framework ceiling · 1 of 6 appointed suppliers
Cancer Medicines (Group 2)The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£18,207,081 †
framework ceiling · 1 of 11 appointed suppliers
About this data
  • One profile per supplier. Built from award and contract notices that name this supplier; different spellings and registration numbers of the same company are merged into this profile.
  • Values are published values. The table mirrors what the notice published: framework ceilings and joint awards are labelled and never counted as this supplier's money, and † marks a value taken from the contract notice when the award published none. Only awards made to this supplier alone count towards its value, excluding VAT. It is not turnover.
  • Regions in the buyer chart describe the buyer office, not where the work is delivered or the supplier’s registered address.
  • Contract end dates. Published on 68 of 122 awards, estimated from the published duration on 31 more (marked “estimated”); those feed “Contracts ending”. Published values in that list come from either source; Contracts Finder figures are shown as published and stay out of this profile’s money totals.
  • Source. Official UK public procurement notices (Find a Tender and Contracts Finder), reused under the Open Government Licence v3.0, updated through the day and rebuilt nightly. Not every figure uses both feeds, and each one shows how many records it rests on: see the methodology. Spotted something wrong? Tell us.